<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55292">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01857232</url>
  </required_header>
  <id_info>
    <org_study_id>DN10016</org_study_id>
    <nct_id>NCT01857232</nct_id>
  </id_info>
  <brief_title>Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy</brief_title>
  <official_title>Randomised, Double-blind, Dose-finding Phase II Study to Assess the Efficacy of APD403 in the Prevention of Nausea and Vomiting Caused by Cisplatin- or Anthracycline/Cyclophosphamide (AC)-Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acacia Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acacia Pharma Ltd</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of efficacy of APD403 at preventing delayed sickness in patients who have
      received cancer chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>24-120 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">315</enrollment>
  <condition>CINV</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron, dexamethasone, fosaprepitant</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Mid dose</arm_group_label>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Male or female patients ≥ 18 years of age

          -  Ability and willingness to give written informed consent

          -  Patients scheduled to receive, on day 1 of their chemotherapy, either: (i) a first
             cisplatin chemotherapy infusion at a dose of ≥70 mg/m2 (males and females); or (ii) a
             first infusion of cyclophosphamide at a dose of 500-1500 mg/m2 in combination with
             either epirubicin at a dose of 60-100 mg/m2 or doxorubicin at a dose of 40-60 mg/m2
             (females only)

          -  Karnofsky performance score ≥ 60%

          -  Adequate cardiac, hepatic and renal function

               -  QTc interval &lt; 500 ms

               -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &lt; 5 x
                  upper limit normal (ULN)

               -  Bilirubin &lt; 5 x ULN

               -  Creatinine &lt; 3 x ULN

          -  Adequate haematological function

               -  Haemoglobin ≥ 8 g/dL

               -  White blood count ≥ 3.0 x 109/L

               -  Platelet count ≥ 100 x 109/L

          -  For females of child-bearing potential: ability and willingness to use a highly
             effective form of contraception (e.g., abstinence from sexual intercourse, surgical
             sterilisation (of subject or partner) or a double-barrier method of contraception
             such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in
             conjunction with partner's use of a condom) during the study and for a period of at
             least 48 hours afterwards

        Exclusion Criteria

          -  Patients scheduled to receive, prior to or in the 120 hours after cisplatin or AC,
             any other chemotherapeutic agent with a high or moderate emetic risk

          -  Patients who have previously received anti-neoplastic chemotherapy

          -  Patients scheduled to receive paclitaxel or docetaxel during the first cycle of their
             chemotherapy

          -  Patients undergoing abdominal or pelvic irradiation within 48 hours prior to
             screening or scheduled to receive abdominal or pelvic irradiation between screening
             and 24 hours after cisplatin or AC administration

          -  Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma
             or confirmed prolactin-dependent breast cancer) or phaeochromocytoma

          -  Patients with a pre-existing vestibular disorder

          -  Patients being treated with regular anti-emetic therapy including corticosteroids

          -  Patients receiving inhaled corticosteroids, unless started more than one month prior
             to the expected date of study entry
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 17, 2013</lastchanged_date>
  <firstreceived_date>May 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
